Back

The gender gap in prescription pattern of Sodium-Glucose Cotransporter 2 inhibitors in patients with Type 2 Diabetes and Coronary Artery Disease

28 August 2023 (15:15 - 15:50)
Organised by: Logo
Congress Presentation Part of: Antidiabetic medications and cardiovascular disease Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Andreas Hammer

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study
Assistant Professor Y. Chen (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
Professor Y. Oh (Seoul, KR)
Abstract Slides
Presentation thumbnail
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
Doctor R. Kani (Kamogawa, JP)
Abstract Slides Video
Presentation thumbnail
GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study
Ms K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor
Doctor C. Chen (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Antidiabetic medications and cardiovascular disease

The Event

Event poster

ESC Congress 2023

28 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care
thumbnail
Congress Presentation
Underprescribing of cardioprotective novel antidiabetic drugs in marginalized patients with type II diabetes mellitus
thumbnail
Congress Presentation
Eligibility and prescribing rates of SGLT2 inhibitors for ambulatory patients with heart failure and reduced ejection fraction in a multidisciplinary heart failure management programme

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources